INTERGRATED DIA.H DL 025 Cash Flow Conversion Efficiency
INTERGRATED DIA.H DL 025 cash flow conversion efficiency. Based on the latest financial reports, INTERGRATED DIA.H DL 025 (8I8) has a cash flow conversion efficiency ratio of 0.096x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€340.79 Million ≈ $398.42 Million USD) by net assets (€3.55 Billion ≈ $4.15 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of INTERGRATED DIA.H DL 025 (2021–2025)
Cash flow conversion efficiency of INTERGRATED DIA.H DL 025 from 2021 to 2025. This chart illustrates how INTERGRATED DIA.H DL 025's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INTERGRATED DIA.H DL 025 (8I8) share price today for real-time trading data and today's change.
INTERGRATED DIA.H DL 025 Cash Flow Conversion Ratio Explained
INTERGRATED DIA.H DL 025 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
INTERGRATED DIA.H DL 025 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of INTERGRATED DIA.H DL 025 ranked by their cash flow conversion efficiency. Also see INTERGRATED DIA.H DL 025 market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clinuvel Pharmaceuticals Ltd
AU:CUV
|
0.050x |
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
-0.094x |
|
WAWEL SA
WAR:WWL
|
0.019x |
|
Zespol Elektrowni Patnow Adamow Konin SA
WAR:ZEP
|
0.081x |
|
NEOBO FASTIGHETER
ST:NEOBO
|
0.006x |
|
P.C.B Tec
TA:PCBT
|
0.056x |
|
Velos Acquisition I Corp.
NASDAQ:VLOS
|
-0.003x |
|
PharmaEngine
TWO:4162
|
0.011x |
Annual Cash Flow Conversion Efficiency for INTERGRATED DIA.H DL 025 (2021–2025)
The table below shows the annual cash flow conversion efficiency of INTERGRATED DIA.H DL 025 from 2021 to 2025. Review INTERGRATED DIA.H DL 025 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.83 Billion |
€1.90 Billion ≈ $2.23 Billion |
0.461x | +2.86% |
| 2024-12-31 | €3.50 Billion ≈ $4.09 Billion |
€1.57 Billion ≈ $1.83 Billion |
0.448x | +155.65% |
| 2023-12-31 | €3.10 Billion ≈ $3.63 Billion |
€543.66 Million ≈ $635.60 Million |
0.175x | +105.54% |
| 2022-12-31 | €2.45 Billion ≈ $2.86 Billion |
€208.73 Million ≈ $244.03 Million |
0.085x | -89.50% |
| 2021-12-31 | €2.79 Billion ≈ $3.27 Billion |
€2.27 Billion ≈ $2.65 Billion |
0.812x | -- |
About INTERGRATED DIA.H DL 025
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more